Thrombolytic

Phase 3Small molecule

FFaculty Hospital Kralovske Vinohrady

Thrombolytic is one of 69 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismRecruiting

COVID-19Active, not recruiting

Pulmonary EmbolismPhase 3

Recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Phase 3

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Tricor

JJagotec

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Benadryl

PParkedale

Preclinical

1 8

Nitrostat

VViatris Specialty LLC

Preclinical

1 9

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

Pulmonary Embolism

NCT05493163

Clinical

Trials by Indication[1]

COVID-191 trial

Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.

Unknown status·YYa-Wei Xu·N/A·NCT05354128·120 enrolled

STEMI1 trial

The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI

Withdrawn·—··NCT03267199

Pulmonary Embolism1 trial

Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

Recruiting·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT05493163·558 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Thrombolytic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombolytic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombolytic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faculty Hospital Kralovske Vinohrady company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFaculty Hospital Kralovske Vinohrady

Thrombolytic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

COVID-191 trial

STEMI1 trial

Pulmonary Embolism1 trial

References

Drug Info

Quick Facts

Related News